References
- Piccart-Gebhart MJ , ProcterM, Leyland-JonesBet al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16) , 1659–1672 (2005).
- Slamon D , EiermannW, RobertNet al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365(14) , 1273–1283 (2011).
- Romond EH , PerezEA, BryantJet al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16) , 1673–1684 (2005).
- Slamon DJ , Leyland-JonesB, ShakSet al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11) , 783–792 (2001).
- Tocchetti CG , RagoneG, CoppolaCet al. Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. Eur. J. Heart Fail. 14(2) , 130–137 (2012).
- Ewer MS , O‘ShaughnessyJA. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin. Breast Cancer.7(8) , 600–607 (2007).
- Mackey JR , ClemonsM, CoteMAet al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr. Oncol. 15(1) , 24–35 (2008).
- Jones AL , BarlowM, Barrett-LeePJet al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br. J. Cancer. 100(5) , 684–692 (2009).
- Ganz WI , SridharKS, GanzSS, GonzalezR, ChakkoS, SerafiniA. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology53(6) , 461–470 (1996).
- Walker J , BhullarN, Fallah-RadNet al. Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J. Clin Oncol. 28(21) , 3429–3436 (2010).
- Haas JS , LiangSY, HassettMJ, ShiboskiS, ElkinEB, PhillipsKA. Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care. Breast Cancer Res. Treat.130(2) , 619–626 (2011).
- Charlson ME , PompeiP, AlesKL, MacKenzieCR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis.40(5) , 373–383 (1987).
- Subar M , LinW, ChenW, PittmanDG. Lack of uniformity in cardiac assessment during trastuzumab therapy. Breast J.17(4) , 383–390 (2011).
- Joensuu H , Kellokumpu-LehtinenPL, BonoP et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354(8) , 809–820 (2006).
▪ Websites
- Genentech, Inc. Herceptin prescribing information, 2012. www.gene.com/gene/products/information/pdf/herceptin-prescribing.pdf (Accessed 1March2013)
- Centers for Medicare & Medicaid Services. Physician Fee Schedule, 2012. www.cms.gov/apps/physician-fee-schedule (Accessed 1March2013)